GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Stem Cell Corp (OTCPK:ISCO) » Definitions » Forward PE Ratio

International Stem Cell (International Stem Cell) Forward PE Ratio : 0.00 (As of Jun. 01, 2024)


View and export this data going back to 2006. Start your Free Trial

What is International Stem Cell Forward PE Ratio?

International Stem Cell's Forward PE Ratio for today is 0.00.

International Stem Cell's PE Ratio without NRI for today is 0.00.

International Stem Cell's PE Ratio for today is 0.00.


International Stem Cell Forward PE Ratio Historical Data

The historical data trend for International Stem Cell's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

International Stem Cell Forward PE Ratio Chart

International Stem Cell Annual Data
Trend
Forward PE Ratio

International Stem Cell Quarterly Data
Forward PE Ratio

Competitive Comparison of International Stem Cell's Forward PE Ratio

For the Biotechnology subindustry, International Stem Cell's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


International Stem Cell's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Stem Cell's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where International Stem Cell's Forward PE Ratio falls into.



International Stem Cell Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


International Stem Cell  (OTCPK:ISCO) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


International Stem Cell Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of International Stem Cell's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


International Stem Cell (International Stem Cell) Business Description

Traded in Other Exchanges
N/A
Address
9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
Executives
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Andrei Semechkin 10 percent owner 1 OVERLOOK DR. UNIT 11, AMHERST NH 03031
Sofya Bakalova officer: Dir. of Legal Affairs & Oper. 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Wright Don director 2829 RUCKER AVE, 3RD FLOOR, EVERETT WA 98201
Jennifer Stephens officer: Acting Chief Financial Officer 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Mahnaz Ebrahimi officer: Chief Financial Officer 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Rouslan Semechkin director, 10 percent owner 2595 JASON CT, OCEANSIDE CA 92056
Tibor Jay Novak officer: Interim CFO 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
John Simon Craw officer: Executive Vice President 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
James H Berglund director C/O INTERNATIONAL STEM CELL CORPORATION, 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Ar Partners Llc 10 percent owner 5950 PRIESTLY DR., CARLSBAD CA 92008
Kurt Andrew May officer: President and COO 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Linh T Nguyen officer: Chief Financial Officer 5950 PRIESTLY DR., CARLSBAD CA 92008
Jeffrey Janus director, officer: President 2595 JASON COURT, OCEANSIDE CA 92056
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027